<clinical_study>
<study_id>
<org_name>
  NIDA
</org_name>
<org_full_name>
  National Institute on Drug Abuse (NIDA)
</org_full_name>
<org_study_id>
  NIDA-00191-2
</org_study_id>
<secondary_id>
  K20-00191-2
</secondary_id>
<nct_id>
  NCT00000193
</nct_id>
</study_id>
<brief_title>
<textblock>
  Neurobiology of Opioid Dependence: 2 - 2
</textblock>
</brief_title>
<official_title>
<textblock>
  Neurobiology of Opioid Dependence: 2
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  National Institute on Drug Abuse (NIDA)
</agency>
</lead_sponsor>
<sponsor>
<agency>
  Yale University
</agency>
</sponsor>
</study_sponsor>
<oversight_info>
<regulatory_authority>
  United States: Federal Government
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Completed
</status>
<date>
  1996-10
</date>
</status_block>
<start_date>
<date>
  1996-01
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date>
<date>
</date>
</last_follow_up_date>
<last_data_entry_date>
<date>
  1996-10
</date>
</last_data_entry_date>
<phase_block>
<phase>
  Phase 2
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Double Blind
</design>
<design>
  Placebo Control
</design>
<primary_outcome>
  Behavioral, subjective, measures of naloxone-preci
</primary_outcome>
<primary_outcome>
  Phsyiological, neuroendocrine measures of naloxone
</primary_outcome>
<condition>
  Opioid-Related Disorders
</condition>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Gamma hydroxybutyric
</primary_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Please contact site for information.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<patients>
</patients>
<expected_enrollment>
  0
</expected_enrollment>
<gender>
  Male
</gender>
<minimum_age>
  N/A
</minimum_age>
<maximum_age>
  N/A
</maximum_age>
</eligibility>
<investigator>
<role>
  Principal Investigator
</role>
<name>
  Marc I Rosen, M.D.
</name>
<affiliation>
<agency>
  VA Connecticut Healthcare System
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Marc I Rosen, M.D.
</name>
<phone>
  (203)932-5711
</phone>
<phone_ext>
  2112
</phone_ext>
<email>
  marc.rosen@yale.edu
</email>
</contact>
<location>
<facility>
<name>
  VA Connecticut Healthcare System
</name>
<address>
<city>
  New Haven
</city>
<state>
  Connecticut
</state>
<zip>
  06519
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  No longer recruiting
</status>
<contact>
<name>
  Marc I Rosen, M.D.
</name>
<phone>
  203-932-5711
</phone>
<phone_ext>
  2112
</phone_ext>
<email>
  marc.rosen@yale.edu
</email>
</contact>
</location>
<background>
<reference>
<citation>
  Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193
</citation>
<medline_ui>
</medline_ui>
</reference>
</background>
<keyword>
</keyword>






</clinical_study>
